TAREK I HASSANEIN
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hepatology
- Where
- CORONADO, CA
- NPI
- 1801854450
- Received
- $339,116 in 375 records, 2019 to 2025 ($278,106 general, $61,009 research)
- As principal investigator
- $5,224,548 of research payments to others in 1,661 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 54 | $48,957 |
| 2024 | General payment | 66 | $48,036 |
| 2023 | General payment | 25 | $39,360 |
| 2022 | General payment | 53 | $35,063 |
| 2021 | General payment | 32 | $14,699 |
| 2021 | Research payment | 1 | $69 |
| 2020 | General payment | 26 | $14,913 |
| 2020 | Research payment | 1 | $6,000 |
| 2019 | General payment | 88 | $77,075 |
| 2019 | Research payment | 29 | $54,939 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 56 | $188,917 |
| Research payment | 31 | $61,009 |
| Consulting Fee | 14 | $43,848 |
| Travel and Lodging | 49 | $25,626 |
| Food and Beverage | 197 | $12,016 |
| Debt forgiveness | 1 | $3,380 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 1 | $3,250 |
| Honoraria | 1 | $750 |
| Education | 25 | $318 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-09 | Madrigal Pharmaceuticals | $9 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-12-01 | GlaxoSmithKline, LLC. | $3,200 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-26 | Gilead Sciences, Inc. | $3,790 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Livdelzi Drug, INFLAM | 2025 | |
| 2025-11-19 | Gilead Sciences, Inc. | $130 | Food and Beverage | In-kind items and services | Livdelzi Drug, INFLAM | 2025 | |
| 2025-11-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $47 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-13 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-12 | Gilead Sciences, Inc. | $3,790 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-11-10 | Gilead Sciences, Inc. | $35 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-09 | Grifols Shared Services North America, Inc. | $124 | Food and Beverage | In-kind items and services | Albutein Biological, Critical Care Medicine | 2025 | |
| 2025-11-09 | ABBVIE INC. | $44 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-11-04 | Gilead Sciences, Inc. | $148 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2025 | |
| 2025-10-24 | Gilead Sciences, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-10-09 | Madrigal Pharmaceuticals | $4,935 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-09 | Madrigal Pharmaceuticals | $966 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-09 | Madrigal Pharmaceuticals | $146 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-08 | Madrigal Pharmaceuticals | $154 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-10-02 | Gilead Sciences, Inc. | $3,790 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2025 | |
| 2025-09-30 | AstraZeneca Pharmaceuticals LP | $32 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-23 | Gilead Sciences, Inc. | $121 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2025 | |
| 2025-09-18 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2025 | |
| 2025-09-03 | Merit Medical Systems Inc | $3,380 | Debt forgiveness | Cash or cash equivalent | 2025 | ||
| 2025-09-02 | ABBVIE INC. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-08-15 | ABBVIE INC. | $34 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-08-07 | Madrigal Pharmaceuticals | $26 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-18 | Madrigal Pharmaceuticals | $5,287 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-18 | Madrigal Pharmaceuticals | $652 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-18 | Madrigal Pharmaceuticals | $244 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-18 | Madrigal Pharmaceuticals | $231 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-07-15 | ABBVIE INC. | $127 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-07-15 | Astellas Pharma US Inc | $34 | Food and Beverage | In-kind items and services | Veozah Drug, Biological | 2025 | |
| 2025-07-11 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-09 | Lilly USA, LLC | $31 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2025 | |
| 2025-06-27 | ABBVIE INC. | $190 | Travel and Lodging | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-06-27 | ABBVIE INC. | $40 | Travel and Lodging | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-06-23 | HISTOSONICS, INC. | $940 | Travel and Lodging (4 payments) | Cash or cash equivalent | 2025 | ||
| 2025-06-05 | Madrigal Pharmaceuticals | $21 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-05-29 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-21 | Madrigal Pharmaceuticals | $3,878 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-05-21 | Madrigal Pharmaceuticals | $112 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-05-02 | Madrigal Pharmaceuticals | $99 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-04-23 | Madrigal Pharmaceuticals | $45 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-04-18 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-04-15 | HISTOSONICS, INC. | $133 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-04-12 | Madrigal Pharmaceuticals | $46 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-04-10 | Inspire Medical Systems, Inc. | $51 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2025 | |
| 2025-04-08 | Madrigal Pharmaceuticals | $108 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2025-04-03 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-03-27 | ABBVIE INC. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-03-25 | Gilead Sciences, Inc. | $3,790 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Livdelzi Drug, INFLAM | 2025 | |
| 2025-03-18 | Gilead Sciences, Inc. | $109 | Food and Beverage | In-kind items and services | Livdelzi Drug, INFLAM | 2025 | |
| 2025-03-18 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-03-06 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-03-04 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2025 | |
| 2025-01-06 | Madrigal Pharmaceuticals | $114 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2025 | |
| 2024-12-19 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-11-26 | Gilead Sciences, Inc. | $3,240 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Livdelzi Drug, INFLAM | 2024 | |
| 2024-11-18 | HISTOSONICS, INC. | $98 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-11-18 | HISTOSONICS, INC. | $31 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-11-16 | Gilead Sciences, Inc. | $113 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-11-15 | Madrigal Pharmaceuticals | $138 | Food and Beverage | In-kind items and services | RESMETIROM Drug, LIVER DISEASE | 2024 | |
| 2024-11-15 | Madrigal Pharmaceuticals | $114 | Food and Beverage | In-kind items and services | RESMETIROM Drug, LIVER DISEASE | 2024 | |
| 2024-11-07 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | 2024 | |
| 2024-11-05 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-10-31 | Gilead Sciences, Inc. | $3,790 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2024 | |
| 2024-10-29 | Gilead Sciences, Inc. | $113 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2024 | |
| 2024-10-15 | ABBVIE INC. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-10-05 | Ipsen Bioscience Inc. | $485 | Travel and Lodging | In-kind items and services | 2024 | ||
| 2024-10-03 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-09-27 | Madrigal Pharmaceuticals | $4,935 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-27 | Madrigal Pharmaceuticals | $520 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-27 | Madrigal Pharmaceuticals | $470 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-27 | Madrigal Pharmaceuticals | $254 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-27 | Madrigal Pharmaceuticals | $226 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-27 | Madrigal Pharmaceuticals | $186 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-27 | Madrigal Pharmaceuticals | $94 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-27 | Madrigal Pharmaceuticals | $80 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-27 | Madrigal Pharmaceuticals | $77 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-25 | Gilead Sciences, Inc. | $4,930 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Livdelzi Drug, INFLAM | 2024 | |
| 2024-09-17 | Gilead Sciences, Inc. | $992 | Travel and Lodging | In-kind items and services | Livdelzi Drug, INFLAM | 2024 | |
| 2024-09-17 | Gilead Sciences, Inc. | $118 | Food and Beverage | In-kind items and services | Livdelzi Drug, INFLAM | 2024 | |
| 2024-09-17 | ABBVIE INC. | $32 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-09-16 | Madrigal Pharmaceuticals | $4,583 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-16 | Madrigal Pharmaceuticals | $218 | Travel and Lodging | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-16 | Madrigal Pharmaceuticals | $144 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-12 | Madrigal Pharmaceuticals | $3,878 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-09-12 | Madrigal Pharmaceuticals | $133 | Food and Beverage | In-kind items and services | REZDIFFRA Drug, LIVER DISEASE | 2024 | |
| 2024-08-26 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-08-24 | Gilead Sciences, Inc. | $776 | Travel and Lodging | In-kind items and services | Livdelzi Drug, INFLAM | 2024 | |
| 2024-08-24 | Gilead Sciences, Inc. | $376 | Travel and Lodging | In-kind items and services | Livdelzi Drug, INFLAM | 2024 | |
| 2024-08-24 | Gilead Sciences, Inc. | $253 | Travel and Lodging | In-kind items and services | Livdelzi Drug, INFLAM | 2024 | |
| 2024-08-24 | Gilead Sciences, Inc. | $142 | Travel and Lodging | In-kind items and services | Livdelzi Drug, INFLAM | 2024 | |
| 2024-08-24 | Gilead Sciences, Inc. | $59 | Food and Beverage | In-kind items and services | Livdelzi Drug, INFLAM | 2024 | |
| 2024-08-24 | Gilead Sciences, Inc. | $55 | Food and Beverage | In-kind items and services | Livdelzi Drug, INFLAM | 2024 | |
| 2024-08-24 | Gilead Sciences, Inc. | $52 | Food and Beverage | In-kind items and services | Livdelzi Drug, INFLAM | 2024 | |
| 2024-08-24 | Gilead Sciences, Inc. | $36 | Food and Beverage | In-kind items and services | Livdelzi Drug, INFLAM | 2024 | |
| 2024-08-22 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-08-15 | Gilead Sciences, Inc. | $3,790 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2024 | |
| 2024-08-13 | Gilead Sciences, Inc. | $121 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2024 | |
| 2024-07-18 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-07-16 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-07-11 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-06-27 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2024 | |
| 2024-06-21 | ABBVIE INC. | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-06-20 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-05-28 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-05-16 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | HUMIRA Biological, IMMUNOLOGY | 2024 | |
| 2024-05-14 | ABBVIE INC. | $109 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-05-12 | HISTOSONICS, INC. | $166 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-05-02 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2024 | |
| 2024-04-19 | HISTOSONICS, INC. | $676 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-04-19 | HISTOSONICS, INC. | $32 | Travel and Lodging | Cash or cash equivalent | 2024 | ||
| 2024-04-18 | Gilead Sciences, Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2024 | ||
| 2024-04-16 | Phathom Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | VOQUEZNA Drug, GASTROENTEROLOGY | 2024 | |
| 2024-04-11 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2024-04-03 | ABBVIE INC. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-03-26 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-03-21 | Kowa Research Institute, Inc. | $899 | Travel and Lodging | Cash or cash equivalent | Drug | 2024 | |
| 2024-03-21 | Kowa Research Institute, Inc. | $400 | Food and Beverage | Cash or cash equivalent | Drug | 2024 | |
| 2024-03-12 | ABBVIE INC. | $108 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2024 | |
| 2024-02-01 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2024 | |
| 2023-11-12 | Ortho Dermatologics, a division of Bausch Health US, LLC | $117 | Food and Beverage | In-kind items and services | XIFAXAN Drug, Gastroenterology | 2023 | |
| 2023-11-10 | Gilead Sciences, Inc. | $105 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-11-07 | ABBVIE INC. | $3,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-11-06 | ABBVIE INC. | $4,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-11-01 | ABBVIE INC. | $1,107 | Travel and Lodging | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-11-01 | ABBVIE INC. | $123 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-10-25 | ABBVIE INC. | $82 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-08-29 | Mallinckrodt Hospital Products Inc. | $5,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TERLIVAZ Drug, CRITICAL CARE | 2023 | |
| 2023-08-23 | Gilead Sciences, Inc. | $3,550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2023 | |
| 2023-08-22 | Mallinckrodt Hospital Products Inc. | $140 | Food and Beverage | In-kind items and services | TERLIVAZ Drug, CRITICAL CARE | 2023 | |
| 2023-08-22 | Eisai Inc. | $29 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-08-08 | Gilead Sciences, Inc. | $107 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2023 | |
| 2023-06-19 | Gilead Sciences, Inc. | $1,780 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2023 | |
| 2023-05-29 | Gilead Sciences, Inc. | $4,620 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epclusa Drug, HCV | 2023 | |
| 2023-05-25 | Gilead Sciences, Inc. | $124 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2023 | |
| 2023-05-16 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-05-15 | ABBVIE INC. | $4,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-05-10 | ABBVIE INC. | $987 | Travel and Lodging | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-05-10 | ABBVIE INC. | $112 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-03-31 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2023 | |
| 2023-03-07 | Gilead Sciences, Inc. | $72 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-03-02 | Celgene Corporation | $12 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-02-27 | Grifols Therapeutics LLC | $2,050 | Consulting Fee | Cash or cash equivalent | Albutein Biological, Critical Care Medicine | 2023 | |
| 2023-02-14 | Mallinckrodt Hospital Products Inc. | $6,890 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TERLIVAZ Drug, CRITICAL CARE | 2023 | |
| 2023-02-10 | Celgene Corporation | $13 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2023 | |
| 2022-12-03 | Mallinckrodt Hospital Products Inc. | $55 | Food and Beverage | In-kind items and services | TERLIVAZ Drug, CRITICAL CARE | 2022 | |
| 2022-12-03 | Mallinckrodt Hospital Products Inc. | $39 | Food and Beverage | In-kind items and services | TERLIVAZ Drug, CRITICAL CARE | 2022 | |
| 2022-12-02 | Mallinckrodt Hospital Products Inc. | $158 | Travel and Lodging | In-kind items and services | TERLIVAZ Drug, CRITICAL CARE | 2022 | |
| 2022-11-30 | Mallinckrodt Hospital Products Inc. | $327 | Travel and Lodging | In-kind items and services | TERLIVAZ Drug, CRITICAL CARE | 2022 | |
| 2022-11-30 | Mallinckrodt Hospital Products Inc. | $318 | Travel and Lodging | In-kind items and services | TERLIVAZ Drug, CRITICAL CARE | 2022 | |
| 2022-11-30 | Mallinckrodt Hospital Products Inc. | $23 | Travel and Lodging | In-kind items and services | TERLIVAZ Drug, CRITICAL CARE | 2022 | |
| 2022-11-22 | Amgen Inc. | $34 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-11-06 | Grifols, S.A. | $118 | Food and Beverage | In-kind items and services | Albutein Biological, Critical Care Medicine | 2022 | |
| 2022-11-05 | ABBVIE INC. | $56 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-11-04 | Gilead Sciences, Inc. | $106 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-10-20 | ABBVIE INC. | $4,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-10-13 | ABBVIE INC. | $904 | Travel and Lodging | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-10-13 | ABBVIE INC. | $125 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-09-28 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-09-27 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-09-13 | Travere Therapeutics, Inc. | $0 | Education | In-kind items and services | Cholbam Drug, Hepatology | 2022 | |
| 2022-08-25 | Grifols Shared Services North America, Inc. | $85 | Food and Beverage | In-kind items and services | Prolastin-C Liquid Biological, Pulmonology | 2022 | |
| 2022-08-10 | ABBVIE INC. | $1,875 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-08-02 | ABBVIE INC. | $3,125 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-07-26 | ABBVIE INC. | $117 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-07-15 | Travere Therapeutics, Inc. | $1 | Education | In-kind items and services | Cholbam Drug, Hepatology | 2022 | |
| 2022-07-15 | Travere Therapeutics, Inc. | $0 | Education | In-kind items and services | Cholbam Drug, Hepatology | 2022 | |
| 2022-06-29 | Travere Therapeutics, Inc. | $6 | Education | In-kind items and services | Cholbam Drug, Hepatology | 2022 | |
| 2022-06-24 | ABBVIE INC. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-06-23 | Janssen Biotech, Inc. | $99 | Education | In-kind items and services | STELARA Biological, Immunology | 2022 | |
| 2022-06-20 | Mallinckrodt Hospital Products Inc. | $5,720 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-06-20 | Mallinckrodt Hospital Products Inc. | $153 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-06-18 | ABBVIE INC. | $514 | Travel and Lodging | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-06-18 | ABBVIE INC. | $294 | Travel and Lodging | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-06-18 | ABBVIE INC. | $65 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-06-18 | ABBVIE INC. | $40 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-06-18 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-06-18 | ABBVIE INC. | $30 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-06-18 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-06-18 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-06-18 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-06-18 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-05-24 | Gilead Sciences, Inc. | $124 | Food and Beverage | In-kind items and services | Epclusa Drug, HCV | 2022 | |
| 2022-05-12 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2022 | |
| 2022-05-10 | Genentech USA, Inc. | $24 | Food and Beverage | In-kind items and services | TECENTRIQ Biological, BioOncology | 2022 | |
| 2022-04-28 | BIOTRONIK INC. | $69 | Food and Beverage | In-kind items and services | BIOMONITOR Device, Cardiology/Vascular Diseases | 2022 | |
| 2022-04-06 | Boston Scientific Corporation | $119 | Food and Beverage | In-kind items and services | WATCHMAN Access System Device, WATCHMAN_IC | 2022 | |
| 2022-04-05 | Boston Scientific Corporation | $50 | Food and Beverage | In-kind items and services | EMBLEM MRI S-ICD Device, EMBLEM_CRM | 2022 | |
| 2022-03-16 | Eisai Inc. | $25 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2022 | |
| 2022-03-16 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-03-07 | ABBVIE INC. | $4,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-03-01 | ABBVIE INC. | $769 | Travel and Lodging | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-03-01 | ABBVIE INC. | $124 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-02-28 | ABBVIE INC. | $4,375 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-02-23 | ABBVIE INC. | $868 | Travel and Lodging | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-02-23 | ABBVIE INC. | $39 | Food and Beverage | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2022-01-28 | Celgene Corporation | $16 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2022 | |
| 2022-01-12 | ABBVIE INC. | $6 | Education | In-kind items and services | MAVYRET Drug, VIROLOGY | 2022 | |
| 2021-11-18 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | HUMIRA Biological, IMMUNOLOGY | 2021 | |
| 2021-11-16 | Mallinckrodt Hospital Products Inc. | $4,647 | Consulting Fee | Cash or cash equivalent | 2021 |
The latest 200 records of 375.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-29 | Janssen Research & Development, LLC | Sthrn California Rsrch Ctr | $2,226 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati | 2025 |
| 2025-12-29 | Janssen Research & Development, LLC | Sthrn California Rsrch Ctr | $3,349 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati | 2025 |
| 2025-12-22 | Novo Nordisk AS | SOUTHERN CALIFORNIA RESEARCH, LLC | $765 | NN9535-4352 | 2025 |
| 2025-12-19 | Regeneron Pharmaceuticals, Inc. | Southern California Research Center | $1,249 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys | 2025 |
| 2025-12-19 | Ipsen Bioscience Inc. | Southern California Research Center | $1,094 | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Saf | 2025 |
| 2025-12-19 | Boehringer Ingelheim International GmbH | Southern California Research Center | $3,399 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | Southern California Research Center | $4 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-12-17 | Boehringer Ingelheim International GmbH | Southern California Research Center | $255 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Southern California Research Center | $2,144 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys | 2025 |
| 2025-12-11 | Ipsen Bioscience Inc. | Southern California Research Center | $44 | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycho | 2025 |
| 2025-11-27 | Boehringer Ingelheim International GmbH | Southern California Research Center | $1,922 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-11-27 | Boehringer Ingelheim International GmbH | Southern California Research Center | $3,399 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-11-27 | Boehringer Ingelheim International GmbH | Southern California Research Center | $1,922 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-11-27 | Boehringer Ingelheim International GmbH | Southern California Research Center | $3,399 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-11-27 | Boehringer Ingelheim International GmbH | Southern California Research Center | $2,655 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-11-25 | Ipsen Bioscience Inc. | Southern California Research Center | $1,037 | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycho | 2025 |
| 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Southern California Research Center | $2,709 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys | 2025 |
| 2025-11-14 | Madrigal Pharmaceuticals | Southern California Research Center | $2,070 | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET | 2025 |
| 2025-11-14 | Madrigal Pharmaceuticals | Southern California Research Center | $2,070 | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET | 2025 |
| 2025-11-14 | Madrigal Pharmaceuticals | Southern California Research Center | $2,423 | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMET | 2025 |
| 2025-11-07 | Regeneron Pharmaceuticals, Inc. | Southern California Research Center | $2,498 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys | 2025 |
| 2025-11-06 | Bausch Health US, LLC | Southern California Research Center | $1,431 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-11-06 | Bausch Health US, LLC | Southern California Research Center | $1,431 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-11-06 | Bausch Health US, LLC | Southern California Research Center | $1,431 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-11-05 | Boehringer Ingelheim International GmbH | Southern California Research Center | $3,399 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-11-05 | Boehringer Ingelheim International GmbH | Southern California Research Center | $1,743 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-11-05 | Boehringer Ingelheim International GmbH | Southern California Research Center | $3,500 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-11-04 | ABBVIE INC. | Southern California Research Center | $222 | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | Southern California Research Center | $292 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | Southern California Research Center | $99 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | Southern California Research Center | $2 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | Southern California Research Center | $151 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | Southern California Research Center | $2,655 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-27 | Janssen Research & Development, LLC | Sthrn California Rsrch Ctr | $3,349 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati | 2025 |
| 2025-10-27 | Janssen Research & Development, LLC | Sthrn California Rsrch Ctr | $2,226 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati | 2025 |
| 2025-10-27 | Boehringer Ingelheim International GmbH | Southern California Research Center | $252 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-27 | Janssen Research & Development, LLC | Sthrn California Rsrch Ctr | $2,226 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati | 2025 |
| 2025-10-23 | Ipsen Bioscience Inc. | South Denver Gastroenterology, Pc | $665 | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Saf | 2025 |
| 2025-10-16 | Regeneron Pharmaceuticals, Inc. | Southern California Research Center | $1,249 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys | 2025 |
| 2025-10-09 | ABBVIE INC. | Southern California Research Center | $11,847 | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | 2025 |
| 2025-10-06 | Bausch Health US, LLC | Southern California Research Center | $1,369 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-10-06 | Bausch Health US, LLC | Southern California Research Center | $1,431 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-10-06 | Bausch Health US, LLC | Southern California Research Center | $2,352 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-10-06 | Bausch Health US, LLC | Southern California Research Center | $1,369 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-10-06 | Bausch Health US, LLC | Southern California Research Center | $2,352 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-10-06 | Bausch Health US, LLC | Southern California Research Center | $1,369 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-10-06 | Bausch Health US, LLC | Southern California Research Center | $1,369 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-10-06 | Bausch Health US, LLC | Southern California Research Center | $1,431 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-10-03 | Boehringer Ingelheim International GmbH | Southern California Research Center | $652 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-03 | Boehringer Ingelheim International GmbH | Southern California Research Center | $2,280 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-03 | Boehringer Ingelheim International GmbH | Southern California Research Center | $652 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-03 | Boehringer Ingelheim International GmbH | Southern California Research Center | $1,922 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-03 | Boehringer Ingelheim International GmbH | Southern California Research Center | $1,922 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-10-03 | Boehringer Ingelheim International GmbH | Southern California Research Center | $2,280 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-09-26 | Boehringer Ingelheim International GmbH | Southern California Research Center | $3,746 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-09-26 | Boehringer Ingelheim International GmbH | Southern California Research Center | $1,743 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-09-26 | Boehringer Ingelheim International GmbH | Southern California Research Center | $1,642 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-09-26 | Boehringer Ingelheim International GmbH | Southern California Research Center | $1,743 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | Southern California Research Center | $79 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | Southern California Research Center | $17 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | Southern California Research Center | $10 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | Southern California Research Center | $10 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | Southern California Research Center | $10 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | Southern California Research Center | $10 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | Southern California Research Center | $43 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | Southern California Research Center | $122 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | Southern California Research Center | $219 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-09-24 | Boehringer Ingelheim International GmbH | Southern California Research Center | $328 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-09-23 | Regeneron Pharmaceuticals, Inc. | Southern California Research Center | $1,249 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys | 2025 |
| 2025-09-19 | Novo Nordisk AS | SOUTHERN CALIFORNIA RESEARCH, LLC | $1,665 | NN9535-4352 | 2025 |
| 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Southern California Research Center | $1,323 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys | 2025 |
| 2025-09-18 | Ipsen Bioscience Inc. | Southern California Research Center | $1,711 | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycho | 2025 |
| 2025-09-17 | Eli Lilly and Company | Southern California Research Center | $10,000 | AN ADAPTIVE, DOSE-RANGING, PHASE 2 STUDY OF ELTREKIBART GIVEN ALONE OR IN COMBINATION WITH MIRIKIZUMAB FOR THE TREATMENT | 2025 |
| 2025-09-12 | Regeneron Pharmaceuticals, Inc. | Southern California Research Center | $4,248 | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dys | 2025 |
| 2025-09-12 | Ipsen Bioscience Inc. | Southern California Research Center | $4,015 | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Saf | 2025 |
| 2025-09-04 | ABBVIE INC. | Southern California Research Center | $3,000 | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy | 2025 |
| 2025-09-03 | Bausch Health US, LLC | Southern California Research Center | $1,431 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-09-03 | Bausch Health US, LLC | Southern California Research Center | $1,369 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-09-03 | Bausch Health US, LLC | Southern California Research Center | $1,754 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-09-03 | Bausch Health US, LLC | Southern California Research Center | $1,754 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-09-03 | Bausch Health US, LLC | Southern California Research Center | $1,431 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-09-03 | Bausch Health US, LLC | Southern California Research Center | $1,754 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-09-03 | Bausch Health US, LLC | Southern California Research Center | $1,431 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-09-03 | ABBVIE INC. | Southern California Research Center | $2,077 | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Mod | 2025 |
| 2025-09-03 | ABBVIE INC. | Southern California Research Center | $6,145 | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | 2025 |
| 2025-09-03 | Bausch Health US, LLC | Southern California Research Center | $2,352 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-09-03 | Bausch Health US, LLC | Southern California Research Center | $2,352 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-09-03 | Bausch Health US, LLC | Southern California Research Center | $2,352 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-09-03 | Bausch Health US, LLC | Southern California Research Center | $1,754 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-09-03 | Bausch Health US, LLC | Southern California Research Center | $2,352 | Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RE | 2025 |
| 2025-08-28 | Boehringer Ingelheim International GmbH | Southern California Research Center | $1,642 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-08-28 | Boehringer Ingelheim International GmbH | Southern California Research Center | $3,500 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-08-28 | Boehringer Ingelheim International GmbH | Southern California Research Center | $4,262 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-08-28 | Boehringer Ingelheim International GmbH | Southern California Research Center | $1,743 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-08-28 | Boehringer Ingelheim International GmbH | Southern California Research Center | $652 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-08-28 | Boehringer Ingelheim International GmbH | Southern California Research Center | $16,049 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-08-28 | Boehringer Ingelheim International GmbH | Southern California Research Center | $1,743 | Safety, tolerability and pharmacodynamics of BI 770371 administered intravenously in patients with compensated cirrhosis | 2025 |
| 2025-08-28 | Boehringer Ingelheim International GmbH | Southern California Research Center | $652 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-08-28 | Boehringer Ingelheim International GmbH | Southern California Research Center | $3,220 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
| 2025-08-28 | Boehringer Ingelheim International GmbH | Southern California Research Center | $16,049 | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Coronado, CA, county San Diego County, CA, state California; placed by its city name.
| Measure | Place (city or town) Coronado, CA | County San Diego County, CA | State California |
|---|---|---|---|
| Population B01003 | 19,015 | 3,288,774 | 39,287,377 |
| Population, 2020 census P1 | 20,192 | 3,298,634 | 39,538,223 |
| Median age B01002 | 42.0 | 37.3 | 37.9 |
| Under 18 B01001 | 17.8% | 20.9% | 22.0% |
| 65 and over B01001 | 22.1% | 15.4% | 15.7% |
| Households B11001 | 7,303 | 1,171,278 | 13,548,091 |
| Foreign born B05002 | 10.1% | 22.8% | 27.0% |
| Median household income B19013 | $134,534 | $106,268 | $99,122 |
| Median family income B19113 | $166,058 | $122,377 | $113,346 |
| Per capita income B19301 | $81,464 | $51,976 | $49,513 |
| Poverty rate B17001 | 4.7% | 10.3% | 12.0% |
| Unemployment rate B23025 | 4.7% | 6.1% | 6.6% |
| Civilian labor force B23025 | 6,805 | 1,689,384 | 20,068,466 |
| Mean commute (minutes) B08013 | 18.1 | 25.5 | 28.7 |
| Bachelor's degree or higher B15003 | 65.5% | 43.2% | 37.1% |
| Housing units B25001 | 9,896 | 1,250,641 | 14,644,735 |
| Owner-occupied B25003 | 54.6% | 54.6% | 55.9% |
| Renters B25003 | 45.4% | 45.4% | 44.1% |
| Median home value B25077 | $2,000,001 | $854,700 | $734,700 |
| Median gross rent B25064 | $3,257 | $2,246 | $2,036 |
| White, not Hispanic B03002 | 67.8% | 42.4% | 33.8% |
| Black B03002 | 2.4% | 4.4% | 5.2% |
| Hispanic or Latino B03002 | 20.2% | 34.6% | 40.2% |
| Asian B03002 | 3.3% | 12.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.4% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Coronado, CA.
Comments